Emerald has two New Chemical Entities (NCEs) in preclinical development; one for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis (SSc) and the other for the treatment of Huntington’s Disease (HD) and Parkinson’s Disease (PD).
The management of Emerald Health Pharmaceuticals (EHP) believes that cannabinoid analogues have the potential to be developed into safe, effective prescription pharmaceutical drugs. The potential ability of cannabis to treat a broad range of health problems and diseases mirrors the wide distribution of cannabinoid receptors present throughout our bodies. This system is called the endocannabinoid system and is responsible for creating homeostasis (i.e., “balance”) in the body and for reducing inflammation, which is the primary cause of many diseases afflicting millions of people worldwide.
EHP leverages the extensive life-science experience of its founders and management, as well as the expertise of its partners, to produce New Chemical Entities (NCEs) derived from cannabis, and to develop the most promising of these NCEs into pharmaceutical drug candidates. The Company currently has two NCEs in preclinical development. One of these NCEs (EHS-101) is derived from cannabidiol (CBD) and is being developed for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis (SSc). The second NCE (EHS-102) is derived from cannabigerol (CBG), and is being developed for the treatment of Huntington’s Disease (HD) and Parkinson’s Disease (PD).
Clinical trials expected to start in 2018
As shown in the following timeline, management’s goal for EHP-101 is to submit a clinical trial application (IND in the US and/or CTA in Europe) by the end of 2017 or early in 2018 and, therefore, could enter clinical development in early to mid 2018.
Annual sales for EHP-101 estimated at $4.7B
Bioscience Valuation GmbH estimates that annual sales for EHP-101 for the treatment of MS will reach US $2.5B a year in a combination of seven major markets and will reach approximately US$2.2B for the treatment of scleroderma as an Orphan Indication.
Building a portfolio of Proprietary NCEs with Composition of Matter Patents
Through a Collaborative Research Agreement with the University of Eastern Piedmont (UPO) in Italy, EHP is building a large portfolio of proprietary NCEs targeted to treat a wide range of human diseases. Composition of matter patents have been filed with respect to these compounds, which, when granted, will provide Emerald with the strongest possible intellectual property protection.
Acquisition kick starts strong IP portfolio
EHP acquired ownership of the composition of matter patent applications related to EHP-101 and EHP-102 from VivaCell Biotechnology España, a privately held, preclinical-stage pharmaceutical company based in Córdoba, Spain, in Q2 2015. VivaCell has been working on the scientific development of cannabinoids since 2003 and is a pioneer in the development of CBD and CBG derivatives targeted to treat human diseases.
VivaCell Biotechnology España
Concurrent with the acquisition of the VivaCell IP in 2015, EHP also acquired 10% ownership of VivaCell, with the purchase of an additional 68% expected to be completed before the end of 2016. Through this acquisition, EHP has acquired rights to various patented drug candidates intended to treat diseases with significant unmet medical need and market potential. In addition, EHP has a right of first refusal on future cannabinoid derivatives developed by VivaCell.